Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patient

Dow Jones

39,118.86

Get Started

Name	Symbol	Market	Type
Amgen Inc	TG:AMGN	Tradegate	Bond

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	-0.072	-0.07%	97.415	97.32	97.51				0	22:50:21

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patient

03/08/2009 10:03pm

PR Newswire (US)

Amgen (TG:AMGN)
Historical Stock Chart

From Jul 2019 to Jul 2024

Second of Three Pivotal Phase Three Bone Metastases Trials Meets Primary Endpoint Denosumab Delayed Time to Skeletal Related Events THOUSAND OAKS, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from a pivotal Phase 3 head-to-head trial evaluating denosumab administered subcutaneously versus Zometa (zoledronic acid) administered as an intravenous (IV) infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. For the primary endpoint, patients treated with denosumab experienced a similar time to first skeletal-related event (SRE) (fracture, radiation to bone, surgery to bone, or spinal cord compression) compared with those receiving Zometa (hazard ratio 0.84, 95 percent CI: 0.71-0.98), which is statistically significant for non-inferiority (p